KURA - Kura Oncology, Inc.
| Previous Close | 19.05 |
| Open | 19.03 |
| Bid | 19.10 x 1200 |
| Ask | 19.09 x 800 |
| Day's Range | 18.79 - 19.29 |
| 52 Week Range | 10.20 - 22.00 |
| Volume | 25,687 |
| Avg. Volume | 357,346 |
| Market Cap | 728.178M |
| Beta (3Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.63 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.00 |
- GlobeNewswire•11 days ago
Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued and the European Patent Office has granted new patents further protecting the Company's lead drug candidate, tipifarnib, a potent and selective farnesyl transferase inhibitor. Tipifarnib is currently being studied in multiple solid tumor and hematologic indications, including a registration-directed clinical trial in HRAS mutant head and neck squamous cell carcinoma (HNSCC).
- Zacks•20 days ago
Kura Oncology, Inc. (KURA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Kura Oncology, Inc. (KURA).
- Simply Wall St.•29 days ago
Do Insiders Own Shares In Kura Oncology, Inc. (NASDAQ:KURA)?
A look at the shareholders of Kura Oncology, Inc. (NASDAQ:KURA) can tell us which group is most powerful. Institutions...
- Simply Wall St.•29 days ago
What Kind Of Investor Owns Most Of Kura Oncology, Inc. (NASDAQ:KURA)?
The big shareholder groups in Kura Oncology, Inc. (NASDAQ:KURA) have power over the company. Insiders often own a...
- GlobeNewswire•last month
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 885,000 shares at the public offering price of $17.00 per share. SVB Leerink and Cowen acted as joint book-running managers for the offering. The securities described above were offered by Kura pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura with the Securities and Exchange Commission (the “SEC”) and that was declared effective on November 21, 2018.
- GlobeNewswire•last month
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its common stock at a price to the public of $17.00 per share. Kura has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of its common stock. The gross proceeds to Kura from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be $100.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Kura. SVB Leerink and Cowen are acting as joint book-running managers for the offering. Wedbush PacGrow and Oppenheimer & Co. are acting as co-lead managers, and H.C. Wainwright & Co. is acting as co-manager for the offering.
- GlobeNewswire•last month
Kura Oncology Announces Commencement of Public Offering of Common Stock
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. SVB Leerink and Cowen are acting as joint book-running managers in the offering. The securities described above are being offered by Kura pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura with the Securities and Exchange Commission (the “SEC”) and that was declared effective on November 21, 2018. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext.
- Insider Monkey•last month
Is Kura Oncology, Inc. (KURA) A Good Stock To Buy?
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- TheStreet.com•last month
Kura Oncology Soars After Lymphoma Treatment Test Results
climbed 6.6% to $19.71 Friday after the clinical-stage biopharmaceutical company said a phase 2 trial of its lymphoma treatment tipifarnib showed encouraging results and achieved its primary endpoint. The San Diego-based company said the results demonstrate ongoing anti-tumor activity and a manageable safety profile in advanced patients with angioimmunoblastic T-cell lymphoma (AITL) as well as non-AITL peripheral T-cell lymphoma (PTCL). "With additional follow up and new patients enrolled in the ongoing Phase 2 study, tipifarnib continues to demonstrate encouraging clinical activity in patients with relapsed or refractory PTCL who have experienced a median of three prior lines of therapy," Francine Foss, professor of medicine at the Yale Cancer Center, and a principal investigator in the trial, said in a statement.
- MarketWatch•last month
Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal
Shares of Kura Oncology Inc. soared 27% toward a record high in premarket trading Friday, after the biopharmaceutical company announced a phase 2 trial of its lymphoma treatment achieved its primary efficacy endpoint. The stock was on track to open above its March 2, 2018 record close of $23.40. The company said the results of the trial demonstrated "ongoing anti-tumor activity and a manageable safety profile" in advanced patients with angioimmunoblastic T-cell lymphoma (AITL), as well as non-AITL relapsed or refractory peripheral T-cell lymphoma (PTCL). "We believe these data support the potential to register tipifarnib in both the AITL and PTCL-NOS patient populations, and we look forward to seeking regulatory feedback on next steps for this program," said Chief Executive Troy Wilson. The stock has run up 32% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 8% and the S&P 500 has advanced 15%.
- GlobeNewswire•last month
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced updated interim data from the ongoing Phase 2 clinical trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The results, which will be presented during an oral session at 16:45 CET / 10:45 am ET tomorrow at the European Hematology Association (EHA) Annual Congress in Amsterdam, demonstrate ongoing anti-tumor activity and a manageable safety profile in advanced patients with angioimmunoblastic T-cell lymphoma (AITL) as well as non-AITL PTCL.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of KURA earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Kura Oncology Inc Earnings Call
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About Kura Oncology, Inc. (KURA)
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
Motley Fool•2 months agoKura Oncology, Inc. (KURA) Q1 2019 Earnings Call Transcript
KURA earnings call for the period ending March 31, 2019.
- Associated Press•2 months ago
Kura Oncology: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 37 cents per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss ...
- GlobeNewswire•2 months ago
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for.
- GlobeNewswire•3 months ago
Kura Oncology to Report First Quarter 2019 Financial Results
SAN DIEGO, April 30, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology,.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of KURA earnings conference call or presentation 5-Mar-19 9:30pm GMT
Q4 2018 Kura Oncology Inc Earnings Call
- GlobeNewswire•4 months ago
Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported new findings regarding the mechanism of action of the Company’s lead drug candidate tipifarnib and its potential clinical applications.
- GlobeNewswire•4 months ago
Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•4 months ago
The Kura Oncology (NASDAQ:KURA) Share Price Has Soared 317%, Delighting Many Shareholders
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. But when you ho...
- GlobeNewswire•5 months ago
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Motley Fool•5 months agoKura Oncology, Inc. (KURA) Q4 2018 Earnings Conference Call Transcript
KURA earnings call for the period ending December 31, 2018.
